Intranasal Immunization With an Attenuated pep27 Mutant Provides Protection From Influenza Virus and Secondary Pneumococcal Infections.
| Autor: | Seung Han Seon, Jung Ah Choi, Eunji Yang, Sukneung Pyo, Man Ki Song, Dong-Kwon Rhee, Seon, Seung Han, Choi, Jung Ah, Yang, Eunji, Pyo, Sukneung, Song, Man Ki, Rhee, Dong-Kwon |
|---|---|
| Předmět: |
RESPIRATORY infections
INFLUENZA A virus IMMUNIZATION MEDICAL microbiology NEURAMINIDASE STREPTOCOCCAL disease prevention INTRANASAL medication ANIMAL experimentation BACTERIAL proteins BIOLOGICAL models BODY weight COMPARATIVE studies RESEARCH methodology MEDICAL cooperation MICE GENETIC mutation PNEUMOCOCCAL vaccines RESEARCH SURVIVAL analysis (Biometry) TOXINS VACCINES EVALUATION research TREATMENT effectiveness ORTHOMYXOVIRUS infections DISEASE complications |
| Zdroj: | Journal of Infectious Diseases; 2/15/2018, Vol. 217 Issue 4, p637-640, 4p |
| Abstrakt: | During influenza pandemics, secondary pneumococcal infections cause excessive mortality. However, the current 13-valent pneumococcal conjugate vaccine, PCV13, provides only limited protection against secondary infection. Therefore, a more effective pneumococcal vaccine is required to protect against secondary pneumococcal infections. Here, intranasal immunization with an attenuated pneumococcal pep27 mutant provides protection from influenza virus infection, and also from secondary pneumococcal challenge. These results indicate that mucosal immunity might be an effective way to reduce the morbidity and mortality due to secondary pneumococcal infections during influenza pandemics. [ABSTRACT FROM AUTHOR] |
| Databáze: | Complementary Index |
| Externí odkaz: |
|